TANDEM DIABETES CARE INC
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- –
- Dividend yield
- –
About Tandem Diabetes Care
Surgical & Medical Instruments & Apparatus, SIC 3841
Tandem Diabetes Care, Inc. develops, manufactures, and sells medical devices and digital tools for diabetes management. The company primarily produces durable insulin pump systems, notably the t:slim X2 and Tandem Mobi, which incorporate its Control-IQ+ automated insulin delivery technology. It also provides disposable supplies, such as insulin cartridges and infusion sets, along with software applications including the Tandem Source data management platform and the Sugarmate mobile app. These products serve individuals with insulin-dependent diabetes, including people with type 1 diabetes and individuals with type 2 diabetes requiring intensive insulin therapy.
The company serves nearly 500,000 customers in more than 25 countries globally. It markets its products in North America and international markets, utilizing direct sales teams and independent distributors across regions such as the United States, Canada, the United Kingdom, Austria, and Switzerland. Device assembly, testing, and packaging activities take place at company facilities located in San Diego, California.
Summary of the business section of Tandem Diabetes Care's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TANDEM DIABETES CARE INC
- Founded
- 2008
- Headquarters
- San Diego, CA
- Address
- 12400 High Bluff Drive 92130
- Phone
- (858) 366-6900
- Website
- www.tandemdiabetes.com
- Employees
- 500,000, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- TNDM
- Exchange
- Nasdaq
- IPO date
- Nov 14, 2013
- Shares outstanding
- 70M, Aug 3, 2026
- Public float
- $1.30B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-10 reverse, Oct 10, 2017; 1-for-10 reverse, Oct 9, 2017
- SEC CIK
- 1438133
- CUSIP
- 875372203
- ISIN
- US8753722037
- LEI
- 549300JEPFOD0K4D3I05
- EIN
- 20-4327508
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John F. Sheridan | PRESIDENT & CEO, Director | 158,425 |
| Rick Carpenter | EVP & Chief Technology Officer | 32,968 |
| Jean-Claude Kyrillos | EVP & Chief Operating Officer | 30,290 |
| Susan Morrison | EVP & Chief Admin. Officer | 52,788 |
| Elizabeth Anne Gasser | EVP, Chief Strategy Officer | 35,534 |
| Leigh Vosseller | EVP & CHIEF FINANCIAL OFFICER | 76,475 |
| Shannon Marie Hansen | EVP & Chief Legal Officer | 33,203 |
| Mark David Novara | EVP & CHIEF COMMERCIAL OFFICER | 37,732 |
| Rebecca B. Robertson | Director | 22,542 |
| Peyton R. Howell | Director | 29,836 |
| Joao Paulo Falcao Malagueira | Director | 22,458 |
| Sandra Beaver | Director | 0 |
| Christopher J. Twomey | Director | 37,114 |
| Rajwant Sodhi | Director | 24,280 |
| Kathleen McGroddy-Goetz | Director | 26,612 |
| Myoungil Cha | Director | 22,458 |
| Kim D. Blickenstaff | Director | 183,038 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 John F. Sheridan | $6.86M | $2.92M | $1.97M | $23 | $99 |
| FY2024 John F. Sheridan | $8.53M | $6.79M | $1.95M | $60 | $105 |
| FY2023 John F. Sheridan | $4.65M | $1.51M | $1.50M | $50 | $106 |
| FY2022 John F. Sheridan | $6.38M | -$8.34M | $1.75M | $75 | $100 |
| FY2021 John F. Sheridan | $5.74M | $16.41M | $1.62M | $253 | $125 |
| FY2020 John F. Sheridan | $3.79M | $11.40M | $1.96M | $161 | $130 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 23, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 16, 2017 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 14, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 8, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |